Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of sunitinib on participants with
ovarian, fallopian tube or peritoneal cancer. Sunitinib is a newly discovered drug that may
stop cancer cells from growing by blocking the blood supply to the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Massachusetts General Hospital